ArticleBritish journal of cancer2026
Neoplasm risk in individuals with neurofibromatosis 1 - a Danish nationwide cohort study with long-term follow-up.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: SomaticFrontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundAs larger population-based studies assessing neoplasm risk in neurofibromatosis 1 (NF1) are limited, we aimed to evaluate overall neoplasm risk, specific cancer types, and second primary cancers.
methodsUsing Danish registries and clinical databases, we identified 2053 individuals with NF1 and 20,530 population comparisons. We calculated cumulative incidences for first and second primary neoplasms for the study population born 1971-2020 and for adult-onset cancers in the study population born 1951-2020. We used multistate models to estimate the probabilities of being neoplasm-free, having one neoplasm, having ≥two neoplasms or being dead at a certain age.
resultsThe 50-year cumulative incidence of any first neoplasm was 27.2% (95% confidence interval [CI] 23.1-31.4%) for NF1 individuals and 5.0% (4.0-6.0%) for comparisons. Moreover, the cumulative incidence of second primary neoplasm was 21.1% (14.4-27.8%) for NF1 individuals and 6.4% (0.0-15.0%) for comparisons 20 years after the first neoplasm. A person born with NF1 had a 69.8% (65.6-74.2%) probability of being alive and without neoplasm history at age 50 compared to 93.5% (92.4-94.6%) for a person without NF1.
conclusionThe highly increased risks for primary and secondary neoplasms and mortality warrant close clinical surveillance of individuals with NF1.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.